Recent Updates
Recently added Catalysts
SNY

Q1 2021 sales increase driven by growth drivers Dupixent and Vaccines Specialty Care sales grew due to strong Dupixent performance ( 1,047 million) and oncology launches Vaccines up driven by PPH franchise and demand for

Key Takeaway: Q1 2021 sales increase driven by growth drivers Dupixent and Progress on implementation of the Corporate Social Responsibility Q1 2021 Change Change at CER IFRS net sales reported 8,591m -4.3 % +2.4 % IFRS net income reported 1,566m -7.0 % IFRS EPS report

Full Press Release Details

Q1 2021 sales increase driven by growth drivers Dupixent and
Progress on implementation of the Corporate Social Responsibility
Q1 2021 Change Change at CER
IFRS net sales reported 8,591m -4.3 % +2.4 %
IFRS net income reported 1,566m -7.0 %
IFRS EPS reported 1.25 -7.4 %
Business operating income 2,638m +4.0 % +13.3 %
Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 7)
2021 first-quarter Sanofi sales
Unless otherwise indicated, all percentage changes in sales in this document are stated at CER1
In the first quarter of 2021, Sanofi sales were 8,591 million, down 4.3% on a reported basis. Exchange rate movements had a negative effect of 6.7
percentage points, mainly driven by the decrease of the U.S. dollar, Brazilian real, Russian ruble, Turkish lira, and Argentine peso and Japanese yen. At CER, Sanofi sales increased 2.4%.
Global Business Units
Total Sales % CER % reported Rest of the world % CER
Dupixent 1,047 45.6 % 34.9 % 793 41.6 % 137 52.2 % 117 71.2 %
Aubagio 500 -1.1 % -7.6 % 339 -5.1 % 132 12.7 % 29 -3.1 %
Lemtrada 24 -44.9 % -51.0 % 10 -52.2 % 5 -61.5 % 9 -15.4 %
Kevzara 57 10.9 % 3.6 % 25 -15.6 % 21 5.0 % 11 333.3 %
Neurology & Immunology 581 -3.4 % -9.9 % 374 -8.3 % 158 5.3 % 49 14.6 %
Cerezyme 178 4.2 % -5.8 % 40 -6.5 % 63 -4.5 % 75 18.4 %
Cerdelga 62 13.8 % 6.9 % 32 12.9 % 26 8.3 % 4 66.7 %
Myozyme 235 0.8 % -4.5 % 88 11.5 % 98 -4.8 % 49 -5.5 %
Fabrazyme 208 4.7 % -2.8 % 93 -2.9 % 57 9.6 % 58 13.8 %
Aldurazyme 66 7.5 % -1.5 % 12 8.3 % 23 9.5 % 31 5.9 %
Rare Disease 770 4.4 % -3.0 % 265 3.2 % 267 0.4 % 238 10.2 %
Jevtana 126 -2.9 % -8.7 % 58 5.0 % 45 -11.8 % 23 -3.7 %
Fasturtec 35 8.6 % 0.0 % 21 4.5 % 11 10.0 % 3 33.3 %
Libtayo 26 125.0 % 116.7 % 0.0 % 22 120.0 % 4 150.0 %
Sarclisa 34 3400.0 % 3300.0 % 12 1200.0 % 13 0.0 % 9 0.0 %
Oncology 221 25.8 % 18.8 % 91 19.3 % 91 28.2 % 39 37.5 %
Alprolix 100 -1.8 % -8.3 % 79 3.6 % 0.0 % 21 -19.2 %
Eloctate 134 -9.9 % -16.8 % 103 -5.0 % 0.0 % 31 -23.8 %
Cablivi 38 66.7 % 58.3 % 22 60.0 % 15 66.7 % 1 0.0 %
Rare Blood Disorder 272 -0.7 % -7.5 % 204 2.8 % 15 66.7 % 53 -20.6 %
Specialty Care 2,891 15.3 % 7.3 % 1,727 15.2 % 668 13.9 % 496 17.6 %
Lantus 652 -3.7 % -9.9 % 192 -8.7 % 125 -16.1 % 335 4.9 %
Toujeo 253 5.1 % -1.6 % 62 0.0 % 94 -5.0 % 97 20.2 %
Soliqua/iGlarLixi 44 29.7 % 18.9 % 26 27.3 % 7 16.7 % 11 44.4 %
0thers Diabetes 226 -7.3 % -13.7 % 44 -11.1 % 64 -7.1 % 118 -5.8 %
Diabetes 1,175 -1.7 % -8.2 % 324 -5.3 % 290 -10.2 % 561 5.3 %
Lovenox 401 30.4 % 21.9 % 13 75.0 % 186 10.5 % 202 50.7 %
Plavix 251 -4.0 % -8.1 % 2 0.0 % 29 -23.7 % 220 -2.1 %
Multaq 72 -3.7 % -11.1 % 62 -4.2 % 6 0.0 % 4 0.0 %
Praluent 56 -20.5 % -23.3 % 5 -81.3 % 36 20.0 % 15 45.5 %
Aprovel 101 -39.7 % -42.0 % 2 -60.0 % 23 -23.3 % 76 -42.4 %
Mozobil 52 1.9 % -3.7 % 28 -6.3 % 14 0.0 % 10 37.5 %
Thymoglobulin 80 1.2 % -5.9 % 46 0.0 % 8 -11.1 % 26 8.0 %
Generics 206 3.5 % -10.8 % 29 -13.5 % 2 0.0 % 175 6.8 %
Others 1,090 -12.2 % -16.7 % 76 -31.4 % 349 -21.6 % 665 -3.3 %
Cardiovascular & Established Rx Products 2,309 -5.6 % -11.5 % 263 -19.0 % 653 -12.0 % 1,393 0.7 %
Industrial Sales 188 8.8 % 3.9 % 11 9.1 % 156 9.0 % 21 8.0 %
General Medicines 3,672 -3.8 % -9.8 % 598 -11.7 % 1,099 -9.0 % 1,975 2.1 %
Pharmaceuticals 6,563 3.8 % -3.0 % 2,325 6.8 % 1,767 -1.5 % 2,471 4.9 %
Polio / Pertussis / Hib 533 14.9 % 10.1 % 135 40.4 % 78 6.8 % 320 8.2 %
Adult Booster Vaccines 100 -8.7 % -13.0 % 48 -3.7 % 34 -26.1 % 18 26.7 %
Meningitis / Pneumonia 128 3.8 % -2.3 % 76 3.8 % 0.0 % 52 3.9 %
Influenza Vaccines 77 23.8 % 22.2 % -100.0 % 9 300.0 % 68 45.8 %
Travel and Other Endemic Vaccines 59 -37.4 % -40.4 % 14 -37.5 % 5 -83.9 % 40 -4.5 %
Vaccines 915 5.3 % 0.7 % 285 7.6 % 127 -16.3 % 503 10.9 %
Allergy 195 -6.2 % -13.3 % 106 3.6 % 18 0.0 % 71 -18.9 %
Cough, Cold and Flu 55 -59.4 % -61.5 % 0.0 % 25 -67.5 % 30 -50.0 %
Pain Care 253 -11.6 % -18.6 % 40 -13.7 % 122 -14.5 % 91 -7.0 %
Digestive Wellness924287-001 283 14.6 % 5.6 % 25 22.7 % 105 0.0 % 153 24.5 %
Physical Wellness 81 2.3 % -5.8 % 0.0 % 8 14.3 % 73 1.3 %
Mental Wellness 53 18.8 % 10.4 % 11 9.1 % 29 15.4 % 13 36.4 %
Personal Care 125 2.2 % -6.7 % 96 1.9 % 1 0.0 % 28 3.3 %
Non-Core / Others 68 -15.3 % -20.0 % 5 66.7 % 26 -33.3 % 37 -4.7 %
Consumer Healthcare 1,113 -7.3 % -14.4 % 283 2.3 % 334 -19.3 % 496 -3.6 %
Company 8,591 2.4 % -4.3 % 2,893 6.4 % 2,228 -5.6 % 3,470 4.3 %
First-quarter 2021 Pharmaceutical sales increased 3.8% to 6,563 million, with double-digit growth of the Specialty Care portfolio mainly driven by
the strong performance of Dupixent which largely offset lower sales in General Medicines in Europe and the U.S.
Net sales ( million) Q1 2021 Change at CER
Total Dupixent 1,047 +45.6 %
In the first quarter, Dupixent (collaboration with Regeneron)
sales were strong despite the COVID-19 environment and increased 45.6% to 1,047 million. In the U.S., Dupixent sales of
793 million (up 41.6%) were driven by continued strong demand in atopic dermatitis (AD) in adult, adolescent patients, and children aged 6 to 11 years, continued uptake in asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP).
Dupixent total prescriptions (TRx) increased 51% (year-over-year) and new-to-brand prescriptions (NBRx)
grew 16% despite fewer in-person physician visits which remain below the pre-COVID level. In Europe, first-quarter
Dupixent sales grew 52.2% to 137 million reflecting continued growth in AD in key countries and additional launches in asthma in European markets. In Japan, sales were
59 million (up 53.7%), where strong demand was moderated by the government price decrease implemented in April 2020. Dupixent was approved in China for the treatment of adults with
moderate-to-severe AD in June 2020 and is listed on the NRDL (National Reimbursement Drug List) as of March 2021. At the end of the first quarter, Dupixent was launched in 49 countries with approximately 260 000 patients on therapy.
Net sales ( million) Q1 2021 Change at CER
Aubagio 500 -1.1 %
Lemtrada 24 -44.9 %
Kevzara 57 +10.9 %
Total Neurology and Immunology 581 -3.4 %
In the first-quarter, Neurology and Immunology sales were down 3.4% to 581 million, impacted primarily by
the decline of Lemtrada sales.
Aubagio sales decreased 1.1% in the first quarter to 500 million, due to lower
sales in the U.S. reflecting increased competition partially offset by demand growth partly related to clinical trial supply and price upside in Europe.
First-quarter Lemtrada sales decreased 44.9% to 24 million, primarily due to the COVID-19 pandemic, which has led to a decrease in infused immune reconstitution therapies such as Lemtrada .
First-quarter Kevzara (collaboration with Regeneron) sales were up 10.9% to
57 million driven by Europe and Rest of the World which largely offset lower U.S. sales reflecting the recent strategic decision to reduce promotional efforts.
Net sales ( million) Q1 2021 Change at CER
Myozyme / Lumizyme 235 +0.8 %
Fabrazyme 208 +4.7 %
Cerezyme 178 +4.2 %
Aldurazyme 66 +7.5 %
Cerdelga 62 +13.8 %
Others Rare Disease 21 +10.0 %
Total Rare Disease 770 +4.4 %
In the first quarter, Rare Disease sales increased 4.4% to 770 million, primarily driven by higher demand
particularly in Rest of the World (up 10.2%). Sales in Europe increased 0.4% and compared to a high base in the first quarter of 2020 due to an inventory build related to the COVID-19 environment.
First-quarter Cerezyme sales increased 4.2% to 178 million, driven by strong
growth in Rest of the World (up 18.4%). First-quarter Cerdelga sales increased 13.8% to 62 million driven by new patient accruals in the three regions. Sales of the
Gaucher franchise (Cerezyme + Cerdelga ) increased 6.5% (to 240 million) in the first quarter.
Myozyme /Lumizyme sales increased 0.8% to 235 million supported by new patient accruals in the U.S.
(up 11.5%) which offset lower sales in Europe and negative phasing effect in Rest of the World.
First-quarter Fabrazyme sales increased 4.7% to 208 million driven by higher sales in Rest of the World and Europe. In the U.S. sales decreased 2.9% reflecting lower treatment compliance during the COVID-19 pandemic.
Net sales ( million) Q1 2021 Change at CER
Jevtana 126 -2.9 %
Fasturtec 35 +8.6 %
Libtayo 26 +125.0 %
Sarclisa 34 +3400.0 %
Total Oncology 221 +25.8 %
First-quarter Oncology sales increased 25.8% to 221 million, driven by the Sarclisa and Libtayo launches.
Jevtana sales decreased 2.9% to 126 million following the entry of generic competition in Europe (down 11.8%) at the end of March. In the U.S., sales were up 5.0%. In the
U.S., the Jevtana composition of matter patent will expire in September 2021. From May to July 2020, Sanofi filed patent infringement suits against all generic filers on Jevtana under Hatch-Waxman in the U.S. District Court for the District of Delaware asserting two method of use patents (US 10,583,110 and US 10, 716,777), both of which expire in October 2030. Sanofi has
reached settlement agreements with some of the defendants and the suit against the remaining defendants currently stayed. In Europe, generic competition has started in certain countries after the expiration of Jevtana s market exclusivity in March 2021.
Libtayo (collaboration with Regeneron) sales were 26 million (up 125.0%) in the first quarter driven by increased demand in metastatic cutaneous squamous cell carcinoma (CSCC) as well as
additional country launches. In February, Libtayo was approved in two new indications in the U.S. as a monotherapy for patients with first-line advanced
non-small cell lung cancer with PD-L1 expression of 50% and for patients with advanced basal cell carcinoma. Libtayo sales in the U.S. are reported by Regeneron.
Sarclisa was approved in March 2020 in the U.S. for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a
proteasome inhibitor and in June by the European Commission in certain adults with RRMM. First-quarter Sarclisa sales were 34 million driven by additional country launches.
First-quarter sales in the U.S. and in Europe were 12 million and 13 million, respectively. In Rest of the World sales ( 9 million) were driven by a strong performance in Japan. At the end of March, the FDA approved
Sarclisa in combination with carfilzomib and dexamethasone for patients with relapsed multiple myeloma.
Net sales ( million) Q1 2021 Change at CER
Eloctate 134 -9.9 %
Alprolix 100 -1.8 %
Cablivi 38 +66.7 %
Total Rare Blood Disorder 272 -0.7 %
In the first quarter, Rare Blood Disorder franchise sales were down 0.7% ( 272 million). Excluding industrial
sales to Sobi, first-quarter sales were up 5.1% driven by Alprolix and Cablivi performance which more than offset Eloctate sales decrease in the U.S. As already communicated, Alprolix and Eloctate
industrial sales to Sobi are expected to be significantly lower in 2021 than in 2020.
Eloctate sales were 134 million in the first quarter, down 9.9%. Excluding
industrial sales to Sobi, Eloctate sales were down 3.4% mainly due to lower U.S. sales (-5.0%) as a result of ongoing competitive pressure. Sales in the Rest of the World were down 23.8% reflecting lower
industrial sales to Sobi.
First-quarter Alprolix sales were down 1.8% to
100 million. Excluding industrial sales to Sobi, Alprolix sales were up 3.0%, mainly driven by patient switches from standard half-life factors and prophylaxis conversion. Sales in the Rest of the World were down 19.2% reflecting lower
industrial sales to Sobi.
Cablivi for the treatment of adults with acquired thrombotic
thrombocytopenic purpura (aTTP), a rare and acute blood disorder, generated sales of 38 million (up 66.7%) in the first quarter of which 22 million from the U.S. (up 60%) driven by increase disease and product awareness as well
as adoption of new ISTH (International Society on Thrombosis and Haemostasis) TTP guidelines. In Europe, sales were 15 million (up 66.7%) driven by new country launches. Globally, diagnosis of the disease and product awareness remain
impacted by the COVID-19 environment.
General Medicines sales were down 3.8% to 3,672 million in the first quarter. Sales of the core
assets2 were 1,474 million up 4.4% (and up 6.3% excluding Praluent U.S. sales3),
driven by strong performance of Lovenox . Non-core assets sales were 2,010 million, down 9.9% reflecting notably portfolio streamlining,
lower Lantus and Aprovel / Avapro sales and some negative COVID-19 impact. First-quarter industrial sales were 188 million up 8.8%.
Net sales ( million) Q1 2021 Change at CER
Lantus 652 -3.7 %
Toujeo 253 +5.1 %
Total glargine 905 -1.4 %
Soliqua 44 +29.7 %
Other diabetes 226 -7.3 %
Total Diabetes 1,175 -1.7 %
In the first quarter, global Diabetes sales decreased 1.7% to 1,175 million. The growth in the Rest of the
World (up 5.3%) was driven by Lantus , Toujeo launch in China and Soliqua
performance. In the U.S., the Diabetes sales decrease 5.3%. In Europe, sales decreased 10.2% largely affected by patient stockpiling related to the COVID-19 environment in the first quarter of 2020.
First-quarter Toujeo sales increased 5.1% to 253 million driven by the launch in
China. Lower sales in Europe reflected the high base in the first quarter 2020 due to patient stockpiling. In the U.S., Toujeo sales were stable with volume growth offsetting average price
Lantus sales were 652 million, down 3.7% in the first quarter,
mainly due to a continued decline in average U.S. net price, increasing usage of Toujeo , biosimilar glargine competition and lower sales in Europe (patient stockpilling in the first quarter
of 2020). In Rest of the World, sales increased 4.9%.
First-quarter Soliqua sales
increased 29.7% to 44 million driven by growth in the three regions and notably by launches in Rest of the World (up 44.4%) and performance in the U.S. (up 27.3%).
Cardiovascular and Established Rx Products
Net sales ( million) Q1 2021 Change at CER
Lovenox * 401 +30.4 %
Plavix * 251 -4.0 %
Aprovel /Avapro 101 -39.7 %
Thymoglobulin 80 +1.2 %
Multaq 72 -3.7 %
Praluent 56 -20.5 %
Mozobil 52 +1.9 %
Generics 206 +3.5 %
Other 1,090 -12.2 %
Total Cardiovascular and Established Rx Products 2,309 -5.6 %
In the first quarter, Cardiovascular and Established Rx Products sales decreased 5.6% to 2,309 million reflecting strong Lovenox growth more than offset in particular by lower sales of Aprovel /Avapro , divestments and some COVID impact.
First-quarter Lovenox sales increased 30.4% to 401 million, driven by Rest of the World (up 50.7%), and Europe (up 10.5%) reflecting demand increase driven by recent guidelines recommending the use of low
molecular weight heparins in hospitalized COVID-19 patients which more than offset biosimilar competition and postponed procedures.
Plavix sales were down 4.0% in the first quarter to 251 million mainly reflecting
lower sales in Europe (down 23.7%) and Japan. In China, first-quarter Plavix sales were 117 million, up 0.8%.
Aprovel /Avapro sales were down 39.7%% to 101 million, primarily reflecting a short-term supply
First-quarter Praluent sales decreased 20.5% to 56 million, due
to lower sales in the U.S. reflecting the restructuring of the collaboration with Regeneron which was effective on April 1, 2020. Sanofi has sole responsibility for Praluent outside the
U.S. while Regeneron has sole responsibility for Praluent in the U.S. Excluding U.S. sales3 , Praluent sales grew 26.8% driven by a strong performance in Europe (up 20.0%) and Rest of the World (up 45.5%) driven by the launch in China.
Praluent was relaunched in Germany at the beginning of April 2021.
Multaq sales were 72 million, down 3.7% in the first quarter due to lower sales in the U.S. impacted by the COVID-19 environment.
Pharmaceuticals business operating income
quarter, business operating income (BOI) of Pharmaceuticals decreased 4.6% to 2,515 million (up 2.9% at CER). The ratio of BOI to net sales decreased by 0.7 percentage points to 38.3%. At CER, the ratio decreased 0.4 percentage
points reflecting higher SG&A spends as well as increased Other operating expenses mainly reflected Regeneron MAbs alliance despite an improvement of the gross margin.
Net sales ( million) Q1 2021 Change at CER
Polio/Pertussis/Hib vaccines
(incl. Hexaxim / Hexyon , Pentacel , Pentaxim and Imovax ) 533 +14.9 %
Influenza vaccines (incl. Vaxigrip , Fluzone HD , Fluzone & Flublok ) 77 +23.8 %
Meningitis/Pneumo vaccines (incl. Menactra ) 128 +3.8 %
Adult Booster vaccines (incl. Adacel ) 100 -8.7 %
Travel and other endemic vaccines 59 -37.4 %
Other vaccines 18 +17.6 %
Total Vaccines 915 +5.3 %
First-quarter Vaccines sales increased 5.3% to 915 million reflecting higher PPH vaccines sales and strong
flu vaccines demand partly offset by lower sales of travel vaccines and adult booster due to the COVID-19 pandemic.
Influenza vaccines sales increased by 23.8% in the first quarter to 77 million, reflecting
strong demand in the southern hemisphere which were partly offset by the U.S. due to the earlier supply to the market as compared to the 2019/2020 flu season.
Last updated: May 11, 2021